Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026)

This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode!

Content:

- Why is lenolidomide (revlimid) our current standard of care?

- What data do we have to add anti CD38 antibodies?

- How is MRD being considered in this space?

** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube